Lurasidone (SM-13496) 是 dopamine D₂ 和 5-HT₇ 的拮抗剂，IC₅₀ 值分别为 1.68 和 0.495 nM。 Lurasidone (SM-13496) 也是 5-HT_1A 受体的部分激动剂，IC₅₀ 值为 6.75 nM。

Lurasidone (SM-13496) is an antagonist of both dopamine D 2 and 5-HT 7 with IC 50 s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of 5-HT 1A receptor with an IC 50 of 6.75 nM.

Solid

5-HT7 Receptor 0.495 nM (IC50) 5-HT1A Receptor

Lurasidone (SM-13496) is an antagonist of dopamine D2 and 5-HT7 with IC50s of 1.68±0.09 and 0.495±0.090 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75±0.97 nM. In vitro receptor binding experiments reveal that Lurasidone (SM-13496) demonstrates affinity for dopamine D2 and 5-HT2A receptors higher than other tested antipsychotics. Lurasidone (SM-13496) does not increase [S]GTPγS binding to the membrane preparations for dopamine D2 receptors by itself, but it antagonizes dopamine-stimulated [S]GTPγS binding in a concentration-dependent manner with a KB value of 2.8±1.1 nM. has not independently confirmed the accuracy of these methods. They are for reference on

Lurasidone (SM-13496) dose-dependently increases the ratio of DOPAC/dopamine in frontal cortex and striatum, but it shows a preferential effect on the frontal cortex compare with the striatum, especially at higher doses. Lurasidone (SM-13496) (ED 50 values 2.3 to 5.0 mg/kg) shows a comparable potency with olanzapine (ED 50 values 1.1 to 5.1 mg/kg), higher potency than clozapine (ED 50 9.5 to 290 mg/kg), and slightly lower potency than haloperidol (ED 50 values 0.44 to 1.7 mg/kg). Lurasidone (SM-13496) (1 to 10 mg/kg) dose-dependently inhibits conditioned avoidance response (CAR) in rats, and the ED 50 values are 6.3 mg/kg. Lurasidone (SM-13496) dose-dependently inhibits tryptamine (TRY)-induced forepaw clonic seizure and p-chloroamphetamine (p-CAMP)-induced hyperthermia with ED 50 values of 5.6 and 3.0 mg/kg, respecti

Room temperature in continental US; may vary elsewhere.

4°C, protect from light 该产品在溶液状态不稳定，建议您现用现配，即刻使用。

[1]. Ishibashi T, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010 Jul;334(1):171-81.
[2]. Sakine Atila Karaca, et al. Development of a validated high-performance liquid chromatographic method for the determination of Lurasidone in pharmaceuticals. Marmara Pharm J. 2017;21 (4): 931-937.

In Vitro: DMSO : 20.83 mg/mL (42.28 mM; Need ultrasonic)Ethanol : 3.33 mg/mL (6.76 mM; ultrasonic and warming and heat to 60°C)配制储备液